Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Anthrax Antitoxins

Procurement

The availability of licensed anthrax antitoxins further expands the options available to treat anthrax infections in an emergency, especially when used appropriately in combination with other anthrax medical countermeasures.

Current Programs

The following BARDA-supported anthrax antitoxins have all been approved by FDA and have been procured for use in the event of an emergency:

  • Anthim:  Anthim, an anthrax antitoxin that was approved by FDA under the Animal Efficacy Rule in March 2016, can be used in combination with antibacterial drugs to treat inhalational anthrax in children and adults. Anthim neutralizes the bacterial toxins that cause the symptoms associated with the disease. Anthim can also be used to prevent inhalational anthrax infection when other therapies are not available.
  • Anthrasil:  Anthrasil, an anthrax therapeutic drug that was approved by FDA in March 2015, is a human immune globulin that is used in combination with antibacterial drugs to treat inhalational anthrax in children and adults.
  • Raxibacumab: Raxibacumab, licensed by the FDA in December 2012, is a monoclonal antibody used in combination with antibacterial drugs to treat inhalational anthrax in children and adults. Raxibacumab neutralizes the bacterial toxins that cause the symptoms associated with anthrax disease.

Future Directions

BARDA will continue to work with its interagency partners, particularly those in the PHEMCE, as they support development of next generation or alternative therapies to treat individuals symptomatic with anthrax disease. 


  • This page last reviewed: March 29, 2019